2023 Q1 Form 10-K Financial Statement

#000117184323001846 Filed on March 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $2.570M $2.763M $12.70M
YoY Change -33.96% -24.53% -8.84%
Cost Of Revenue $1.094M $1.516M $5.996M
YoY Change -36.05% -3.23% 4.32%
Gross Profit $1.477M $1.246M $6.702M
YoY Change -32.33% -40.47% -18.08%
Gross Profit Margin 57.45% 45.11% 52.78%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $127.0K $125.9K $490.8K
YoY Change -3.57% -2.84% 2.53%
% of Gross Profit 8.6% 10.1% 7.32%
Depreciation & Amortization $24.46K $32.55K $135.4K
YoY Change -28.61% -16.65% -7.25%
% of Gross Profit 1.66% 2.61% 2.02%
Operating Expenses $127.0K $600.7K $490.8K
YoY Change -3.57% -18.47% 2.53%
Operating Profit $831.8K $645.8K $4.037M
YoY Change -44.69% -52.42% -28.76%
Interest Expense $120.3K $198.5K -$809.6K
YoY Change -134.08% 329.03% -483.96%
% of Operating Profit 14.47% 30.74% -20.05%
Other Income/Expense, Net $120.3K -$809.6K
YoY Change -134.08% -483.97%
Pretax Income $952.2K $844.3K $3.228M
YoY Change -17.26% -39.84% -45.09%
Income Tax $196.1K $165.1K $658.2K
% Of Pretax Income 20.59% 19.55% 20.39%
Net Earnings $756.1K $679.2K $2.570M
YoY Change -17.05% -39.16% -44.84%
Net Earnings / Revenue 29.42% 24.58% 20.23%
Basic Earnings Per Share $0.16 $0.56
Diluted Earnings Per Share $0.16 $0.15 $0.56
COMMON SHARES
Basic Shares Outstanding 4.594M 4.594M 4.594M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.972M $6.484M $6.484M
YoY Change -10.57% -20.6% -20.6%
Cash & Equivalents $1.202M $830.5K $830.5K
Short-Term Investments $5.770M $5.654M $5.654M
Other Short-Term Assets $319.5K $387.1K $387.1K
YoY Change -31.67% 100.99% 100.99%
Inventory $2.470M $1.672M $1.672M
Prepaid Expenses
Receivables $1.481M $1.428M $1.428M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.24M $9.971M $9.971M
YoY Change -8.69% -13.92% -13.92%
LONG-TERM ASSETS
Property, Plant & Equipment $537.3K $559.2K $559.2K
YoY Change -14.64% -15.13% -15.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $161.1K $110.5K $110.5K
YoY Change
Total Long-Term Assets $698.4K $669.7K $669.7K
YoY Change 10.95% 1.65% 1.65%
TOTAL ASSETS
Total Short-Term Assets $11.24M $9.971M $9.971M
Total Long-Term Assets $698.4K $669.7K $669.7K
Total Assets $11.94M $10.64M $10.64M
YoY Change -7.73% -13.09% -13.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $441.5K $30.42K $30.42K
YoY Change 20.04% -92.6% -92.6%
Accrued Expenses $1.314M $1.322M $1.322M
YoY Change -14.31% -18.76% -18.76%
Deferred Revenue $140.8K $0.00
YoY Change 59.01% -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.918M $1.374M $1.374M
YoY Change -4.62% -41.24% -41.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.918M $1.374M $1.374M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.918M $1.374M $1.374M
YoY Change -13.17% -43.26% -43.26%
SHAREHOLDERS EQUITY
Retained Earnings $9.563M $8.807M
YoY Change -6.91% -5.92%
Common Stock $459.4K $459.4K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.02M $9.267M $9.267M
YoY Change
Total Liabilities & Shareholders Equity $11.94M $10.64M $10.64M
YoY Change -7.73% -13.09% -13.09%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $756.1K $679.2K $2.570M
YoY Change -17.05% -39.16% -44.84%
Depreciation, Depletion And Amortization $24.46K $32.55K $135.4K
YoY Change -28.61% -16.65% -7.25%
Cash From Operating Activities $417.6K $624.7K $2.525M
YoY Change 1423.21% -62.47% -52.47%
INVESTING ACTIVITIES
Capital Expenditures $2.582K $15.01K $75.18K
YoY Change -46.65% -143.66% -35.4%
Acquisitions
YoY Change
Other Investing Activities -$43.51K $1.148M $972.7K
YoY Change 2.88% -3.87% -1549.69%
Cash From Investing Activities -$46.09K $1.133M $897.6K
YoY Change -2.21% -2.32% -589.2%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00 $3.123M
YoY Change -39.82%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 -1.424M -$3.123M
YoY Change -52.3% -39.82%
NET CHANGE
Cash From Operating Activities $417.6K 624.7K $2.525M
Cash From Investing Activities -$46.09K 1.133M $897.6K
Cash From Financing Activities $0.00 -1.424M -$3.123M
Net Change In Cash $371.5K 333.9K $299.2K
YoY Change -1984.55% -307.79% -596.82%
FREE CASH FLOW
Cash From Operating Activities $417.6K $624.7K $2.525M
Capital Expenditures $2.582K $15.01K $75.18K
Free Cash Flow $415.0K $609.7K $2.450M
YoY Change 1738.35% -64.11% -52.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
20063 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
20252 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4594319
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4594319
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4594319
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4594319
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022 ug Number Of Vendors
NumberOfVendors
6 pure
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2021 ug Defined Contribution Plan Employer Discretionary Contribution Amount Per Year Authorized
DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized
109000 usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
1-10526
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-1719724
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
230 Marcus Blvd.
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Hauppauge
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11788
CY2022 dei City Area Code
CityAreaCode
631
CY2022 dei Local Phone Number
LocalPhoneNumber
273-0900
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $.10 par value
CY2022 dei Trading Symbol
TradingSymbol
UG
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
68868800 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4594319
CY2022 dei Auditor Firm
AuditorFirmId
23
CY2022 dei Auditor Name
AuditorName
Baker Tilly US, LLP
CY2022 dei Auditor Location
AuditorLocation
Uniondale, NY
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13929629 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5996376 usd
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5747931 usd
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2174127 usd
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2035970 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
490770 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
478642 usd
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
8661273 usd
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
8262543 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
4037230 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
5667086 usd
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
236695 usd
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
233857 usd
CY2022 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-1046245 usd
CY2021 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-23018 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-809550 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
210839 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3227680 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5877925 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
658168 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1219383 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2569512 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
4658542 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.01
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4594319
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4594319
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
830452 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
531213 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
5653516 usd
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7635463 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1427576 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1813346 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1672012 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1410789 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
201846 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
192579 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
185228 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9970630 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11583390 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
110544 usd
CY2022Q4 us-gaap Land
Land
69000 usd
CY2021Q4 us-gaap Land
Land
69000 usd
CY2022Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
4585055 usd
CY2021Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
4605742 usd
CY2022Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
2895742 usd
CY2021Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
2853718 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7549797 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7528460 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6990636 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6869598 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
559161 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
658862 usd
CY2022Q4 us-gaap Assets
Assets
10640335 usd
CY2021Q4 us-gaap Assets
Assets
12242252 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
30415 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
410894 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1322056 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1627390 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
190164 usd
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
88738 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
21220 usd
CY2021Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
20575 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1373691 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2337761 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
83222 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
459432 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
459432 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
8807212 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
9361837 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9266644 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
9821269 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10640335 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12242252 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10354307 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
4658542 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
9821269 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2569512 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
9266644 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
2569512 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
4658542 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135396 usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
145977 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2445 usd
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
14799 usd
CY2022 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-1046245 usd
CY2021 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-23018 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-189 usd
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6235 usd
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
29000 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-193766 usd
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-68462 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-385959 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
431883 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
290223 usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4984 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9267 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
31371 usd
CY2022 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
185228 usd
CY2021 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-99107 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-380479 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
379094 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-305334 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
263933 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-190164 usd
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
190164 usd
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-88738 usd
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
88738 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2525169 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5313277 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75179 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
116375 usd
CY2022 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
37039 usd
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1931969 usd
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4219760 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2867671 usd
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4152660 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
897562 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-183475 usd
CY2022 us-gaap Payments Of Dividends
PaymentsOfDividends
3123492 usd
CY2021 us-gaap Payments Of Dividends
PaymentsOfDividends
5190033 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3123492 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5190033 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
299239 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60231 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
531213 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
591444 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
830452 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
531213 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1125000 usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1100000 usd
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
645 usd
CY2021Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1547 usd
CY2021 ug Tradein Received From Sale Of Asset
TradeinReceivedFromSaleOfAsset
29000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Use of Estimates</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/>
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
20063 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
20252 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
190164 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13929629 usd
CY2021Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Cost
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost
7466168 usd
CY2021Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Fair Value
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue
7635463 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13929629 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
105000 usd
CY2022Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.37
CY2022Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.31
CY2022 us-gaap Dividends
Dividends
3124137 usd
CY2022 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
3123492 usd
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
645 usd
CY2021Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.48
CY2021Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.65
CY2021 us-gaap Dividends
Dividends
5191580 usd
CY2021 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
5190033 usd
CY2021Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1547 usd
CY2021Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Unrealized Gain Loss
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss
169295 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2867671 usd
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Concentration of Credit Risk</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended <em style="font: inherit;"> December 31, 2022, </em><span style="-sec-ix-hidden:c95656233">four</span> of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 72% of the Company’s gross sales during the year and approximately 81% of its outstanding accounts receivable at <em style="font: inherit;"> December 31, 2022. </em>For the year ended <em style="font: inherit;"> December 31, 2021, </em>the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 75% of the Company’s gross sales during the year and 80% of its outstanding accounts receivable at <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/>
CY2021 ug Number Of Vendors
NumberOfVendors
6 pure
CY2022 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-364074 usd
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4152660 usd
CY2021 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
111917 usd
CY2022 us-gaap Advertising Expense
AdvertisingExpense
19000 usd
CY2021 us-gaap Advertising Expense
AdvertisingExpense
31000 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
437775 usd
CY2022Q4 ug Deferred Tax Liabilities Accounts Receivable
DeferredTaxLiabilitiesAccountsReceivable
304004 usd
CY2021Q4 ug Deferred Tax Liabilities Accounts Receivable
DeferredTaxLiabilitiesAccountsReceivable
385056 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
830452 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
531213 usd
CY2022 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
-1046245 usd
CY2021 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
-23018 usd
CY2022 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-364074 usd
CY2021 us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
111917 usd
CY2022 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
-682171 usd
CY2021 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
-134935 usd
CY2022Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
6166392 usd
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
5653516 usd
CY2022Q4 ug Equity Securities Fvni Accumulated Unrealized Gain Loss
EquitySecuritiesFvniAccumulatedUnrealizedGainLoss
-512876 usd
CY2022Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Cost
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost
6166392 usd
CY2022Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Fair Value
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue
5653516 usd
CY2022Q4 ug Debt Securities Held To Maturity And Equity Securities Fvni Unrealized Gain Loss
DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss
-512876 usd
CY2021Q4 us-gaap Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
7466168 usd
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
7635463 usd
CY2021Q4 ug Equity Securities Fvni Accumulated Unrealized Gain Loss
EquitySecuritiesFvniAccumulatedUnrealizedGainLoss
169295 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
601125 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
494348 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
16520 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
119069 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1054367 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
797372 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1672012 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
1410789 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
64000 usd
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
35000 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
850344 usd
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1287749 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1590 usd
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
96 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
851934 usd
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1287845 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-193766 usd
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-68462 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-193766 usd
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-68462 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
658168 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1219383 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
42446 usd
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
38918 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
44812 usd
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
61471 usd
CY2021Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
35552 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
677813 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1234364 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1256 usd
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
76 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
10000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.003 pure
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
10000 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.002 pure
CY2022 us-gaap Income Tax Reconciliation Deductions Dividends
IncomeTaxReconciliationDeductionsDividends
6300 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Deductions Dividends
EffectiveIncomeTaxRateReconciliationDeductionsDividends
0.002 pure
CY2021 us-gaap Income Tax Reconciliation Deductions Dividends
IncomeTaxReconciliationDeductionsDividends
2923 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation Deductions Dividends
EffectiveIncomeTaxRateReconciliationDeductionsDividends
0.001 pure
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-4601 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001 pure
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-2134 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
658168 usd
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.204 pure
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1219383 usd
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.207 pure
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
4213 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
4253 usd
CY2022Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
13440 usd
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
7350 usd
CY2022Q4 ug Deferred Tax Assets Accounts Payable
DeferredTaxAssetsAccountsPayable
6367 usd
CY2021Q4 ug Deferred Tax Assets Accounts Payable
DeferredTaxAssetsAccountsPayable
86288 usd
CY2022Q4 ug Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
92756 usd
CY2022Q4 us-gaap Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross
DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross
107704 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
277326 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
339884 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
501806 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
391262 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
520997 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
110544 usd
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
83222 usd
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
81000 usd
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
80000 usd
CY2022 ug Defined Contribution Plan Employer Discretionary Contribution Amount Per Year Authorized
DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized
109000 usd
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
13905962 usd
CY2021 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
14947167 usd
CY2022 ug Sales Returns And Allowances
SalesReturnsAndAllowances
1207459 usd
CY2021 ug Sales Returns And Allowances
SalesReturnsAndAllowances
1017538 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13929629 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12698503 usd
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13929629 usd
CY2022 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
13905962 usd
CY2021 ug Revenue From Contract With Customer Including Assessed Tax Gross
RevenueFromContractWithCustomerIncludingAssessedTaxGross
14947167 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
175496 usd
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
348000 usd
CY2022Q4 ug Accrued Distribution Fees Current
AccruedDistributionFeesCurrent
395536 usd
CY2021Q4 ug Accrued Distribution Fees Current
AccruedDistributionFeesCurrent
359550 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
53475 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
292560 usd
CY2022Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
94326 usd
CY2021Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
109000 usd
CY2022Q4 ug Accrued Annual Report Expenses Current
AccruedAnnualReportExpensesCurrent
68349 usd
CY2021Q4 ug Accrued Annual Report Expenses Current
AccruedAnnualReportExpensesCurrent
64038 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
66500 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
61500 usd
CY2022Q4 ug Accrued Reserve For Outdated Material
AccruedReserveForOutdatedMaterial
369154 usd
CY2021Q4 ug Accrued Reserve For Outdated Material
AccruedReserveForOutdatedMaterial
313904 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
80926 usd
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
56857 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18294 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21981 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1322056 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1627390 usd
CY2022Q4 ug Convertible Common Stock Shares Issuable Upon Conversion
ConvertibleCommonStockSharesIssuableUponConversion
447
CY2022 ug Payments For Accrued Dividends On Unconverted Shares
PaymentsForAccruedDividendsOnUnconvertedShares
447 usd

Files In Submission

Name View Source Status
0001171843-23-001846-index-headers.html Edgar Link pending
0001171843-23-001846-index.html Edgar Link pending
0001171843-23-001846.txt Edgar Link pending
0001171843-23-001846-xbrl.zip Edgar Link pending
ex_488286.htm Edgar Link pending
ex_488287.htm Edgar Link pending
ex_488288.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ug-20221231.xsd Edgar Link pending
ug20221231_10k.htm Edgar Link pending
ug-20221231_lab.xml Edgar Link unprocessable
ug-20221231_pre.xml Edgar Link unprocessable
ug20221231_10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
ug-20221231_def.xml Edgar Link unprocessable
ug-20221231_cal.xml Edgar Link unprocessable